Inhibrx Biosciences Long Term Debt

Inhibrx Biosciences (INBX) currently reports a long-term debt of $2.9M as of June 2026. That compares with $5.3M in the prior-year period — down 46.6% year over year. Use the charts on this page to explore Inhibrx Biosciences's long-term debt history and peer comparisons.

Inhibrx Biosciences's long-term debt decreased from $5.3M to $2.9M — a 46.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Inhibrx Biosciences reported $2.9M in long-term debt as of June 2026. That compares with $5.3M in the prior-year period — down 46.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $2.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Inhibrx Biosciences, and consider following INBX for alerts when major investors trade the stock.

Inhibrx Biosciences is classified in the Healthcare sector. On long-term debt, it currently shows $2.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INBX with unrelated industries.